SurModics, Inc. (SRDX)

NASDAQ: SRDX · IEX Real-Time Price · USD
35.38
-0.53 (-1.48%)
May 16, 2022 4:00 PM EDT - Market closed
Market Cap494.97M
Revenue (ttm)96.95M
Net Income (ttm)-10.47M
Shares Out13.99M
EPS (ttm)-0.76
PE Ration/a
Forward PE34.36
Dividendn/a
Ex-Dividend Daten/a
Volume33,269
Open35.59
Previous Close35.91
Day's Range35.01 - 36.85
52-Week Range32.43 - 62.27
Beta1.02
AnalystsBuy
Price Target75.48 (+113.3%)
Earnings DateApr 27, 2022

About SRDX

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to pr...

IndustryHealth Care Equipment & Supplies
IPO DateMar 4, 1998
CEOGary Maharaj
Employees389
Stock ExchangeNASDAQ
Ticker SymbolSRDX
Full Company Profile

Financial Performance

In 2021, SurModics's revenue was $105.14 million, an increase of 10.83% compared to the previous year's $94.86 million. Earnings were $4.24 million, an increase of 277.29%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SRDX stock is "Buy." The 12-month stock price forecast is 75.48, which is an increase of 113.34% from the latest price.

Price Target
$75.48
(113.34% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

2 weeks ago - Zacks Investment Research

SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Surmodics Reports Second Quarter Fiscal 2022 Results

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Reports Second Quarter Fiscal 2022 Results

2 weeks ago - Business Wire

Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium

3 weeks ago - Business Wire

Surmodics to Webcast Second Quarter Fiscal 2022 Earnings Conference Call on April 27

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Webcast Second Quarter Fiscal 2022 Earnings Conference Call on April 27.

3 weeks ago - Business Wire

Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

1 month ago - Zacks Investment Research

Surmodics to Host Virtual Annual Meeting of Shareholders

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Host Virtual Annual Meeting of Shareholders on February 10, 2022 at 4:00 p.m. (CT)

3 months ago - Business Wire

SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Surmodics Reports First Quarter Fiscal 2022 Results

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Reports First Quarter Fiscal 2022 Results

3 months ago - Business Wire

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Surmodics to Webcast First Quarter Fiscal 2022 Earnings Conference Call on February 3

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Catheter--Surmodics to Webcast First Quarter Fiscal 2022 Earnings Conference Call on February 3. Webcast is Live at 7:30 a.m. (CT)

3 months ago - Business Wire

Surmodics to Present at Sidoti & Company Virtual Investor Conference

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Present at Sidoti & Company Virtual Investor Conference on January 19, 2022.

4 months ago - Business Wire

Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat

Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.

6 months ago - Zacks Investment Research

SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 60.00% and 6.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance

6 months ago - Business Wire

Surmodics to Webcast Fourth Quarter Fiscal 2021 Earnings Conference Call on November 10

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Webcast Fourth Quarter Fiscal 2021 Earnings Conference Call on November 10. Webcast is Live at 7:30 a.m. (CT)

6 months ago - Business Wire

Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool

Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.

7 months ago - Zacks Investment Research

Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter

7 months ago - Business Wire

HRC vs. SRDX: Which Stock Is the Better Value Option?

HRC vs. SRDX: Which Stock Is the Better Value Option?

8 months ago - Zacks Investment Research

Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates

Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.

9 months ago - Zacks Investment Research

SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of -54.55% and -0.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Recap: Surmodics Q3 Earnings

Shares of Surmodics (NASDAQ:SRDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 180.95% year over year to ($0.17), which were in line with the esti...

9 months ago - Benzinga

Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #IVD--Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance

9 months ago - Business Wire

Surmodics Announces Successful First Patient Use of Pounce™ Thrombectomy System

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #510K--Surmodics Announces Successful First Patient Use of Pounce™ Thrombectomy System

9 months ago - Business Wire

Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research